Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trialBirgit Geoerger, Navin Pinto, Margaret E. Macy et al.|The Lancet Oncology|2019Cited by 341
An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 PatientsNicole G. Chau, Christopher A. French, Clement Ma et al.|JNCI Cancer Spectrum|2019Cited by 226
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G. DuBois, Araz Marachelian, Yaël P. Mossé et al.|Clinical Cancer Research|2018Cited by 88
Opportunities and Challenges in Drug Development for Pediatric CancersTheodore W. Laetsch, Lucas Moreno, Steven G. DuBois et al.|Cancer Discovery|2020Cited by 70
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancerAlanna J. Church, Katherine A. Janeway, Laura Corson et al.|Nature Medicine|2022Cited by 65